Literature DB >> 26756409

Role of CT perfusion imaging in patients with variously differentiated gastric adenocarcinoma.

Zong-Qiong Sun1, Xiao-Fang Cheng2, Yu-Xi Ge1, Lin Chen1, Jian-Guo Yue1, Lin-Fang Jin3, Zhi-Hui Xie4, Han-Di Zhang5, Ying-Hua Xuan6.   

Abstract

PURPOSE: To explore the characteristics of variously differentiated gastric cancers on computed tomography (CT) perfusion imaging, including specific perfusion parameter values, and potential clinical applications in the prognosis assessment of gastric cancer.
MATERIALS AND METHODS: Fifty patients with gastric cancer confirmed by gastroscope pathology were studied prospectively using CT perfusion imaging examinations on a 64-slice spiral CT scanner. The acquired volume data were used for calculations, mapping, and analysis by using an abdominal tumor perfusion protocol (deconvolution method) in the CT perfusion software package to measure 4 parameters: blood flow (BF), blood volume (BV), mean transit time (MTT), and the permeability surface (PS) area product. The different differentiated Gastric cancers with CT perfusion values were divided into 3 groups: well-differentiated, moderately differentiated and poorly differentiated gastric adenocarcinoma, and compared statistically with one another by statistical software.
RESULTS: The mean perfusion values of 10 patients with well-differentiated gastric adenocarcinoma were as follows: BF, 75.28 ± 6.81 mL/100 g/min; BV, 9.01 ± 0.94 mL/100 g; MTT, 9.89 ± 1.65 s; and PS, 10.05 ± 0.71 mL/100 g/min. The mean perfusion values of 24 patients with moderately differentiated gastric adenocarcinoma were as follows: BF, 110.01 ± 31.90 mL/100 g/min; BV, 18.18 ± 5.62 mL/100 g; MTT, 9.81 ± 3.69 s; and PS, 40.08 ± 15.82 mL/100 g/min. The mean perfusion values of 16 patients with poorly differentiated gastric adenocarcinoma were as follows: BF, 138.59 ± 38.09 mL/100 g/min; BV, 21.08 ± 4.11 mL/100 g; MTT, 9.47 ± 1.80 s; and PS, 57.50 ± 13.28 mL/100 g/min. Comparing the 3 groups, differences between the well-differentiated group and the moderate differentiation group were all statistically significant for BF, BV, and PS (p < 0.05, respectively), differences between the well-differentiated group and the poor differentiation group were all statistically significant for BF, BV, and PS (p < 0.05,respectively) as well; While MTT value showed no statistical difference among the 3 groups (p > 0.05).
CONCLUSION: Stomach CT perfusion imaging is a functional imaging technology from the perspective of hemodynamics with potential clinical applications. The BF, BV and PS values could serve as indicators of the degree of malignancy and aid in prognostic assessment of gastric cancer.

Entities:  

Keywords:  CT; Gastric cancer; differentiation; perfusion imaging; prognosis

Mesh:

Year:  2015        PMID: 26756409     DOI: 10.3233/XST-150524

Source DB:  PubMed          Journal:  J Xray Sci Technol        ISSN: 0895-3996            Impact factor:   1.535


  4 in total

1.  Can lymphovascular invasion be predicted by preoperative multiphasic dynamic CT in patients with advanced gastric cancer?

Authors:  Zelan Ma; Changhong Liang; Yanqi Huang; Lan He; Cuishan Liang; Xin Chen; Xiaomei Huang; Yabing Xiong; Zaiyi Liu
Journal:  Eur Radiol       Date:  2016-12-20       Impact factor: 5.315

2.  Evaluation of Multislice Spiral Computed Tomography Perfusion Imaging for the Efficacy of Preoperative Concurrent Chemoradiotherapy in Middle-aged and Elderly Patients with Locally Advanced Gastric Cancer.

Authors:  Jian-Xiao Liang; Xiu-Juan Bi; Xiao-Mei Li; Zhen-Li Gao; Feng Suo; En-Gang Cui; Hong-Fu Li; Hai-Lian Lv
Journal:  Med Sci Monit       Date:  2018-01-12

3.  Observation of the effect of targeted therapy of 64-slice spiral CT combined with cryoablation for liver cancer.

Authors:  Qiao-Huan Yan; Dian-Guo Xu; Yan-Feng Shen; Ding-Ling Yuan; Jun-Hui Bao; Hai-Bin Li; Ying-Gang Lv
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

Review 4.  A Systematic Review on the Role of the Perfusion Computed Tomography in Abdominal Cancer.

Authors:  Nunzia Garbino; Valentina Brancato; Marco Salvatore; Carlo Cavaliere
Journal:  Dose Response       Date:  2021-11-24       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.